Diels J, et al. - Researchers used individual patient data (IPD) from randomized controlled trials to evaluate the relative effectiveness of guselkumab, first approved monoclonal antibody that inhibits IL-23 by targeting its p19 subunit with high specificity and affinity, and ustekinumab, an anti-IL-12/IL-23 monoclonal antibody that binds to the p40 subunit shared by IL-12 and IL-23, for maintenance therapy of moderate-to-severe plaque psoriasis. For the achievement and maintenance of Psoriasis Area and Severity Index (PASI) 90, 75 and 100 responses up to 40 weeks, multivariable logistic regression analyses contrasted guselkumab 100 mg and ustekinumab 45 mg or 90 mg. Adjusted analyses leveraging IPD show that guselkumab has a significantly greater likelihood of achieving and sustaining PASI treatment responses through week 40 than ustekinumab does.